Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. (Nasdaq: COCP) is a clinical-stage biotechnology company discovering and developing small-molecule antiviral therapies for serious and chronic viral diseases. Its research targets influenza, norovirus, coronaviruses, including SARS-CoV-2, and hepatitis C, using a proprietary structure-based… From the company’s description.
In fiscal 2025, Cocrystal Pharma, Inc. reported a net loss of $8.83M. Operations used $8.19M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Cocrystal Pharma, Inc. does
In the company’s own words
Cocrystal Pharma, Inc. (Nasdaq: COCP) is a clinical-stage biotechnology company discovering and developing small-molecule antiviral therapies for serious and chronic viral diseases. Its research targets influenza, norovirus, coronaviruses, including SARS-CoV-2, and hepatitis C, using a proprietary structure-based drug-discovery platform that combines computational and medicinal chemistry with X-ray crystallography. The company operates as one business entity and has no commercialized products. Its pipeline includes CC-42344, an influenza A PB2 inhibitor; CDI-988, a norovirus and coronavirus protease inhibitor in a Phase 1b norovirus challenge study; and CC-31244, an HCV polymerase inhibitor for which the company is seeking a development partner. The company’s candidates are intended to inhibit viral replication, with programs spanning preclinical through early clinical development. Cocrystal had 10 full-time employees as of December 31, 2025, eight of whom worked in clinical advancement and research and development; it also uses external research, manufacturing and clinical-development providers. Its website is www.cocrystalpharma.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BOTHELL, WA
- Fiscal year end
- December
- CIK
- 1412486
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Cocrystal Pharma, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Cocrystal Pharma, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Cocrystal Pharma, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Cocrystal Pharma, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Cocrystal Pharma, Inc.'s last four quarterly filings that the numbers alone won't show?”